1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
EXHIBIT 10.119
THIRD AMENDMENT TO AGREEMENT
This is the third amendment to the Research Collaboration and License
Agreement between MERCK & CO., INC., a corporation organized and existing under
the laws of New Jersey ("MERCK") and ARRIS PHARMACEUTICAL CORPORATION, a
corporation organized and existing under the laws of Delaware, now known as Axys
Pharmaceuticals, Inc. ("Axys") made as of November 6, 1996 (the "Agreement").
The purpose of this third amendment is to extend the Research Program Term
through November 5, 2000, and to increase the number of FTEs for the period
September 1, 1999 through November 5, 2000.
1. In accordance with the provisions of Section 2.8 and Section 5.2(d)
of the Agreement and subject to MERCK's right to terminate the Research Program
and the Agreement in accordance with Section 8.2, the Research Program Term is
extended through November 5, 2000, and the parties agree that [ * ] FTEs will be
required during the period September 1, 1999 through November 5, 2000. The FTEs
for the period September 1, 1999 through November 5, 1999 shall be payable at an
annual rate of [ * ] per FTE. The FTEs for the period November 6, 1999 through
November 5, 2000 shall be payable at an annual rate of [ * ] per FTE.
2. Attachment 2.1 setting forth the Research Program is hereby amended
to include the additional research work set forth on the attachment to this
third amendment.
3. Capitalized terms used and not otherwise defined herein shall have
the respective meanings set forth in the Agreement. The Agreement, together with
the first amendment dated February 9, 1998, the second amendment dated November
5, 1998 and this third amendment contain the entire understanding of the parties
with respect to their subject matter. All express or implied agreements and
understandings, either oral or written, heretofore made are expressly merged in
and made a part of the Agreement as amended by the first, second and third
amendments. All other terms and conditions of the Agreement, as amended,
continue in full force and effect. The Agreement and its amendments may be
amended, or any term thereof modified, only by a written instrument duly
executed by both parties hereto.
IN WITNESS WHEREOF, the parties have entered into this Amendment as of
18 November, 1999.
MERCK & CO., INC. AXYS PHARMACEUTICAL, INC.
BY: /s/ Xxxxx X. Xxxxxxxxxx, M.D., Ph.D. BY: /s/ Xxxx X. Xxxxxx
------------------------------------ -------------------------
Xxxxx X. Xxxxxxxxxx, M.D., Ph.D. Xxxx X. Xxxxxx
Executive Vice President Chairman
Worldwide Basic Research Chief Executive Officer
And Preclinical Development
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
1.
2
Attachment 2.1
Research Program
ATTACHMENT 2.1
RESEARCH PROGRAM
The work outlined below, initiated [ * ], will be completed by [ * ].
1. [ * ]
[ * ]
2. [ * ]
[ * ]
3. [ * ]
[ * ]
4. [ * ]
[ * ]
5. [ * ]
[ * ]
6. [ * ]
[ * ]
7. [ * ]
a. [ * ]
b. [ * ]
c. [ * ]
d. [ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
1.
3
Attachment 2.1
Research Program
APPENDIX A
[ * ]
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
2.
4
Attachment 2.1
Research Program
APPENDIX B
[ * ]
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
3.
5
Attachment 2.1
Research Program
APPENDIX C
[ * ]
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
4.
6
Attachment 2.1
Research Program
APPENDIX D
[ * ]
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
5.
